The FDA has accepted the new drug application (NDA) for tirabrutinib (ONO-4059), a highly selective, irreversible, second-generation Bruton tyrosine kinase (BTK) inhibitor developed for the treatment ...
The prominent role of the BCR signaling in promoting B-CLL cell survival has prompted new therapeutic strategies targeted to signalosome elements. In particular, the most advanced BCR-signaling ...
B Cells are a type of lymphocyte whose primary purpose is to generate highly specific antibodies in response to a foreign antigen. B Cells are a type of lymphocyte whose primary purpose is to generate ...
Association of increased progression-free survival in primary glioblastomas with lymphopenia at baseline and activation of NK and NKT cells after dendritic cell immunotherapy. Comparison of ...
Clinical significance of gastrointestinal involvement in human immunodeficiency virus (HIV) patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Phase I study of recombinant human ...
A review of current data identified areas of progress in Bruton tyrosine kinase (BTK) inhibition for patients with chronic lymphocytic leukemia (CLL). Virtually every medication carries pros and cons, ...
This article was supported by Regione Veneto, Ricerca Sanitaria Finalizzata; Fondazione G Berlucchi per la Ricerca sul Cancro; Fondazione Cassa di Risparmio di Verona, Vicenza, Belluno e Ancona and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results